Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.
Lancet (London, England)|October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate dataClaire L Vale, David Fisher, Andrew Kneebone, et al.
Clinical Genitourinary Cancer|March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 StudyStéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
European Urology|May 20, 2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 TrialMatthew D Galsky, Michiel S van der Heijden, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
The New England Journal of Medicine|October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial CarcinomaMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
JAMA Oncology|February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical TrialStéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
Pageof 18